Literature DB >> 25352888

Basis of selection of first and second line highly active antiretroviral therapy for HIV/AIDS on genetic barrier to resistance: a literature review.

Christine Katusiime1, Ponsiano Ocama2, Andrew Kambugu1.   

Abstract

The effectiveness of combination antiretroviral therapy (cART) continues to improve as treatment choices expand with the development of new antiretroviral agents and regimens. However, the successful long-term treatment of HIV/AIDS is under threat from the emergence of drug-resistant strains to multiple agents and entire drug classes.

Entities:  

Keywords:  HIV resistance; genetic barrier; highly active antiretroviral therapy

Mesh：

Substances：

Year:  2014        PMID： 25352888      PMCID： PMC4209633          DOI： 10.4314/ahs.v14i3.25

Source DB:  PubMed          Journal:  Afr Health Sci        ISSN： 1680-6905            Impact factor:   0.927


  15 in total

1.  Protease inhibitors: resistance, resistance, resistance.

Authors:  D Gilden; J Falkenberg; G Torres
Journal:  GMHC Treat Issues       Date:  1997-02

2.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.

Authors:  Dale J Kempf; Martin S King; Barry Bernstein; Paul Cernohous; Eric Bauer; Jennifer Moseley; Kai Gu; Ann Hsu; Scott Brun; Eugene Sun
Journal:  J Infect Dis       Date:  2003-12-31       Impact factor: 5.226

Review 3.  Genetic barriers to resistance and impact on clinical response.

Authors:  Andrew D Luber
Journal:  MedGenMed       Date:  2005-07-07

Review 4.  Resistance to HIV protease inhibitors.

Authors:  J H Condra
Journal:  Haemophilia       Date:  1998-07       Impact factor: 4.287

5.  The treatment of antiretroviral-naive subjects with the 3TC/zidovudine combination: a review of North American (NUCA 3001) and European (NUCB 3001) trials.

Authors:  J J Eron
Journal:  AIDS       Date:  1996-12       Impact factor: 4.177

6.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

7.  Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel.

Authors:  Martin S Hirsch; Françoise Brun-Vézinet; Bonaventura Clotet; Brian Conway; Daniel R Kuritzkes; Richard T D'Aquila; Lisa M Demeter; Scott M Hammer; Victoria A Johnson; Clive Loveday; John W Mellors; Donna M Jacobsen; Douglas D Richman
Journal:  Clin Infect Dis       Date:  2003-06-23       Impact factor: 9.079

Review 8.  Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance.

Authors:  Joel E Gallant; Peter Z Gerondelis; Mark A Wainberg; Nancy S Shulman; Richard H Haubrich; Marty St Clair; Ernest R Lanier; Nicholas S Hellmann; Douglas D Richman
Journal:  Antivir Ther       Date:  2003-12

Review 9.  Lopinavir/ritonavir: a protease inhibitor for HIV-1 treatment.

Authors:  Patricia Barragan; Daniel Podzamczer
Journal:  Expert Opin Pharmacother       Date:  2008-09       Impact factor: 3.889

10.  Lopinavir/ritonavir in the treatment of HIV-1 infection: a review.

Authors:  Ashish Chandwani; Jonathan Shuter
Journal:  Ther Clin Risk Manag       Date:  2008-10       Impact factor: 2.423
View more
  1 in total

1.  Ebola and other issues in the health sector in Africa.

Authors:  J K Tumwine
Journal:  Afr Health Sci       Date:  2014-09       Impact factor: 0.927
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.